About vistagen therapeutics inc - VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
VTGN At a Glance
Vistagen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, California 94080
| Phone | 1-650-577-3600 | Revenue | 1.27M | |
| Industry | Biotechnology | Net Income | -69,685,000.00 | |
| Sector | Health Technology | 2026 Sales Growth | 161.111% | |
| Fiscal Year-end | 03 / 2027 | Employees | 41 | |
| View SEC Filings |
VTGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 17.147 |
| Price to Book Ratio | 0.637 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.317 |
| Enterprise Value to Sales | -17.809 |
| Total Debt to Enterprise Value | -0.046 |
VTGN Efficiency
| Revenue/Employee | 30,951.22 |
| Income Per Employee | -1,699,634.146 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.019 |
VTGN Liquidity
| Current Ratio | 3.669 |
| Quick Ratio | 3.669 |
| Cash Ratio | 3.548 |
VTGN Profitability
| Gross Margin | 42.238 |
| Operating Margin | -5,683.688 |
| Pretax Margin | -5,490.78 |
| Net Margin | -5,491.332 |
| Return on Assets | -104.864 |
| Return on Equity | -131.593 |
| Return on Total Capital | -190.584 |
| Return on Invested Capital | -130.122 |
VTGN Capital Structure
| Total Debt to Total Equity | 2.939 |
| Total Debt to Total Capital | 2.855 |
| Total Debt to Total Assets | 2.15 |
| Long-Term Debt to Equity | 0.701 |
| Long-Term Debt to Total Capital | 0.681 |